Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Polysaccharide-encapsulated organisms such as S. pneumoniae, H. influenzae type b and N. meningitidis are the leading causes of serious invasive bacterial diseases and pneumonia in children. The use of conjugate vaccines in developed countries has markedly decreased the burden of disease and mortality from these organisms through direct protection of the immunised and through herd immunity. Although conjugate vaccines are highly immunogenic, antibody levels after immunisation in early infancy wane, leading to the need for programmes which include booster doses. Understanding the generation of long-term immunity could lead to improvements in vaccine formulation and scheduling with the ultimate goal of providing more sustained protection. Prematurity is a risk factor for disease caused by polysaccharide-encapsulated bacteria and the available data indicate that preterm infants should be immunised according to their chronological age to provide early protection.

Original publication

DOI

10.1016/j.earlhumdev.2010.08.010

Type

Journal article

Journal

Early Hum Dev

Publication Date

11/2010

Volume

86

Pages

695 - 701

Keywords

Bacterial Infections, Bacterial Vaccines, Child, Child, Preschool, Haemophilus Infections, Haemophilus Vaccines, Humans, Immunization, Secondary, Infant, Infant, Newborn, Infant, Premature, Meningitis, Meningococcal, Meningococcal Vaccines, Vaccination, Vaccines, Conjugate